Peru has suspended trials for China’s Sinopharm Covid-19 vaccine due to a “serious adverse event” that occurred with one of the volunteers for the study, the Peruvian government said in a statement on Saturday (Dec 12).
The health ministry said the event is “under investigation to determine if it is related to the vaccine or if there is another explanation.”
According to reports, after taking the shot, the test volunteer started exhibiting neurological problems, prompting a temporary halt to the exercise.
Sinopharm Group conducted its trials in Peru with about 12,000 volunteers. They were due to complete the first stage of the trials in the next few days.
“Several days ago we signalled, as we are required, to the regulatory authorities that one of our participants (in trials) presented neurological symptoms which could correspond to a condition called Guillain-Barre syndrome,” said chief researcher German Malaga in comments to the press.
Guillain-Barre syndrome is a rare and non-contagious disorder which affects the movement of the arms and legs.
Some 36,544 people have died so far in Peru from the coronavirus pandemic.
NEWS/PHOTO SOURCE: News Agencies